- Home
- Publications
- Publication Search
- Publication Details
Title
Tubulin: an example of targeted chemotherapy
Authors
Keywords
-
Journal
Future Medicinal Chemistry
Volume 5, Issue 3, Pages 339-352
Publisher
Future Science, LTD
Online
2013-03-06
DOI
10.4155/fmc.12.217
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale
- (2012) E. Komlodi-Pasztor et al. CLINICAL CANCER RESEARCH
- A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
- (2012) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer
- (2011) K. Aogi et al. ANNALS OF ONCOLOGY
- Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials
- (2011) T. Reiman et al. ANNALS OF ONCOLOGY
- Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer
- (2011) Xiaosong Chen et al. CANCER SCIENCE
- Class III -Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized Trial
- (2011) A. C. Vilmar et al. CLINICAL CANCER RESEARCH
- Chemotherapy-Induced Peripheral Neuropathy: Prevention and Treatment
- (2011) D R Pachman et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Eribulin mesylate in patients with refractory cancers: a Phase I study
- (2011) Toru Mukohara et al. INVESTIGATIONAL NEW DRUGS
- Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer
- (2011) Ken Kato et al. INVESTIGATIONAL NEW DRUGS
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
- (2011) Ingrid E. Wertz et al. NATURE
- Mitosis is not a key target of microtubule agents in patient tumors
- (2011) Edina Komlodi-Pasztor et al. Nature Reviews Clinical Oncology
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma
- (2010) A. Y. Bedikian et al. ANNALS OF ONCOLOGY
- Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer
- (2010) Chris Twelves et al. Clinical Breast Cancer
- Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine
- (2010) Javier Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2010) Joseph A. Sparano et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer
- (2010) Mary E.R. O'Brien et al. Journal of Thoracic Oncology
- Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer
- (2010) Petr Zatloukal et al. Journal of Thoracic Oncology
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Microtubule-binding agents: a dynamic field of cancer therapeutics
- (2010) Charles Dumontet et al. NATURE REVIEWS DRUG DISCOVERY
- Chemotherapy-induced peripheral neurotoxicity
- (2010) Guido Cavaletti et al. Nature Reviews Neurology
- Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy
- (2009) Or A. Shemesh et al. ACTA NEUROPATHOLOGICA
- North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer
- (2009) E. A. Perez et al. ANNALS OF ONCOLOGY
- Relationship between GSTP1 Ile105Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity
- (2009) O. Mir et al. ANNALS OF ONCOLOGY
- Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability
- (2009) Jennifer A. Smith et al. BIOCHEMISTRY
- Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III β-tubulin
- (2009) Antonella Pepe et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors
- (2009) A. R. Tan et al. CLINICAL CANCER RESEARCH
- Overexpression of Class III -Tubulin Predicts Good Response to Taxane-Based Chemotherapy in Ovarian Clear Cell Adenocarcinoma
- (2009) D. Aoki et al. CLINICAL CANCER RESEARCH
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
- (2009) A. C. Mita et al. CLINICAL CANCER RESEARCH
- From signaling pathways to microtubule dynamics: the key players
- (2009) Sandrine Etienne-Manneville CURRENT OPINION IN CELL BIOLOGY
- Significantly Longer Progression-Free Survival Withnab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
- (2009) William J. Gradishar et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2009) Linda T. Vahdat et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing
- (2009) Bruce E. Hillner et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10
- (2009) Charles A. Butts et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer
- (2009) Corey J. Langer et al. Journal of Thoracic Oncology
- Ixabepilone: targeting III-tubulin expression in taxane-resistant malignancies
- (2009) C. Dumontet et al. MOLECULAR CANCER THERAPEUTICS
- Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy
- (2008) V. Dieras et al. ANNALS OF ONCOLOGY
- A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
- (2008) X. Pivot et al. ANNALS OF ONCOLOGY
- Non-anti-mitotic concentrations of taxol reduce breast cancer cell invasiveness
- (2008) Truong-An Tran et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial
- (2008) George Pentheroudakis et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
- (2008) L Paz-Ares et al. BRITISH JOURNAL OF CANCER
- Preclinical discovery of ixabepilone, a highly active antineoplastic agent
- (2008) Francis Y. F. Lee et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preclinical efficacy spectrum and pharmacokinetics of ixabepilone
- (2008) Francis Y. F. Lee et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Phase I/II Study of Ixabepilone plus Capecitabine in Anthracycline–Pretreated/Resistant and Taxane-Resistant Metastatic Breast Cancer
- (2008) Craig Bunnell et al. Clinical Breast Cancer
- Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel
- (2008) D. LOVEN et al. EUROPEAN JOURNAL OF CANCER CARE
- Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?
- (2008) Pascal Sève et al. LANCET ONCOLOGY
- Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel
- (2008) Koichi Azuma et al. LUNG CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started